Summary
- By inhibiting multiple targets simultaneously, the anti-cancer molecule cabozantinib is showing stellar efficacy and safety in treating various cancer types.
- While procuring meaningful revenues, the development of cabozantinib for a vast number of cancer indications ensures strong future sales growth.
- Most of the clinical trials studying cabozantinib will highly likely post positive future results.
- Despite the recent run-up in share price, there are substantial values to be unlocked in the aforesaid tyrosine kinases inhibitor.
Background
As part of the biotech bull run that commenced in late 2016, Exelixis, Inc. (NASDAQ: EXEL) rewarded shareholders with more than four-folds appreciation in share price for the past year. Based in San Francisco, California, the firm is focusing on the development and commercialization of molecules to improve the outcome and care for patients afflicted by cancers. While it is seemingly the market sentiment that share price is trading at a premium, our analytical research proved otherwise. There is substantial unlocked value in the cabozantinib franchises that, in and of itself, ensures aggressive future sales growth. And despite that the company has a highly enriched pipeline, we shall evaluate the prospects of cabozantinib alone in this research.
To learn more how Dr. Tran BioSci can serve your specific needs ...
(If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights).
To access the complete article, please go to the premier investing research platform Seeking Alpha.
